Losing weight in the CAMELLIA-TIMI 61 trial was associated with a significantly reduced risk for developing type 2 diabetes, the investigators have reported at the 54th EASD Annual Meeting in Berlin, Germany.
Findings from a dose-ranging phase II trial published in The Lancet suggest that semaglutide, in combination with lifestyle intervention, may aid weight loss in people with obesity who do not have diabetes.
The National Institute For Health and Care Excellence has issued an evidence summary to support use of the glucagon-like peptide-1 receptor agonist liraglutide in obese and overweight individuals with risk factors, such as dysglycemia.
A patient affected by obesity discusses her experience of living with the disease and using many different weight loss approaches until finding a lifestyle program that was appropriate for her metabolism.
Taking the glucagon-like peptide-1 receptor agonist liraglutide does not increase patients’ risk for acute pancreatitis during more than 3 years of treatment, show two reports analyzing the LEADER and SCALE trials.